Silexion Therapeutics LTD

0.95
-0.04 (-4.23%)
At close: Apr 03, 2025, 2:14 PM

Silexion Therapeutics LTD Statistics

Share Statistics

Silexion Therapeutics LTD has - shares outstanding. The number of shares has increased by null% in one year.

Shares Outstanding -
Shares Change (YoY) n/a
Shares Change (QoQ) n/a
Owned by Institutions (%) n/a
Shares Floating -
Failed to Deliver (FTD) Shares 22.82K
FTD / Avg. Volume 0.16%

Short Selling Information

The latest short interest is 35.84K, so 0.9% of the outstanding shares have been sold short.

Short Interest 35.84K
Short % of Shares Out 0.9%
Short % of Float 1.71%
Short Ratio (days to cover) 0.23

Valuation Ratios

The PE ratio is 0.99 and the forward PE ratio is -3.17. Silexion Therapeutics LTD's PEG ratio is 0.

PE Ratio 0.99
Forward PE -3.17
PS Ratio 0
Forward PS null
PB Ratio -8192.41
P/FCF Ratio -1.95
PEG Ratio 0
Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for Silexion Therapeutics LTD.

EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 0.64, with a Debt / Equity ratio of -263.

Current Ratio 0.64
Quick Ratio 0.64
Debt / Equity -263
Debt / EBITDA -
Debt / FCF -0.06
Interest Coverage 0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity n/a
Return on Assets n/a
Return on Invested Capital n/a
Revenue Per Employee $-
Profits Per Employee $-
Employee Count undefined
Asset Turnover 0
Inventory Turnover n/a

Taxes

Income Tax 0
Effective Tax Rate 0%

Stock Price Statistics

The stock price has increased by null% in the last 52 weeks. The beta is 0.11, so Silexion Therapeutics LTD's price volatility has been higher than the market average.

Beta 0.11
52-Week Price Change null%
50-Day Moving Average 1.22
200-Day Moving Average null
Relative Strength Index (RSI) 40.73
Average Volume (20 Days) 14.29M

Income Statement

Revenue n/a
Gross Profit 0
Operating Income 0
Net Income 16.51M
EBITDA 0
EBIT n/a
Earnings Per Share (EPS) 2.03
Full Income Statement

Balance Sheet

The company has 0 in cash and 526K in debt, giving a net cash position of -526K.

Cash & Cash Equivalents 0
Total Debt 526K
Net Cash -526K
Retained Earnings -43.25M
Total Assets 2.86M
Working Capital -1.27M
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -8.4M and capital expenditures -22K, giving a free cash flow of -8.42M.

Operating Cash Flow -8.4M
Capital Expenditures -22K
Free Cash Flow -8.42M
FCF Per Share -1.03
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin n/a
Pretax Margin n/a
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

SLXN does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Payout Ratio n/a
Earnings Yield n/a
FCF Yield n/a
Dividend Details

Analyst Forecast

The average price target for SLXN is $5, which is 400% higher than the current price. The consensus rating is "Buy".

Price Target $5
Price Target Difference 400%
Analyst Consensus Buy
Analyst Count 1
Stock Forecasts

Stock Splits

The last stock split was on Nov 29, 2024. It was a backward split with a ratio of 1:9.

Last Split Date Nov 29, 2024
Split Type backward
Split Ratio 1:9

Scores

Altman Z-Score -40.05
Piotroski F-Score 1